Expected Net Present Value of Sample Information: from burden to investment

Peter S Hall; Richard Edlin; Samer A. Kharroubi; Walter Gregory; Christopher McCabe

doi:10.1177/0272989X12443010

Expected Net Present Value of Sample Information: from burden to investment

Peter S Hall, Richard Edlin, Samer A. Kharroubi, Walter Gregory, Christopher McCabe

Mathematics

Research output: Contribution to journal › Article

Abstract

The Expected Value of Information Framework has been proposed as a method for identifying when health care technologies should be immediately reimbursed and when any reimbursement should be withheld while awaiting more evidence. This framework assesses the value of obtaining additional evidence to inform a current reimbursement decision. This represents the burden of not having the additional evidence at the time of the decision. However, when deciding whether to reimburse now or await more evidence, decision makers need to know the value of investing in more research to inform a future decision. Assessing this value requires consideration of research costs, research time, and what happens to patients while the research is undertaken and after completion. The investigators describe a development of the calculation of the expected value of sample information that assesses the value of investing in further research, including an only-in-research strategy and an only-with-research strategy.

Original language	English
Pages (from-to)	E11-E21
Number of pages	10
Journal	Medical Decision Making
Volume	32
Issue number	3
DOIs	https://doi.org/10.1177/0272989X12443010
Publication status	Published - May 2012

Keywords

Statistics

Access to Document

10.1177/0272989X12443010

http://mdm.sagepub.com/content/early/2012/04/26/0272989X12443010

Cite this

@article{7bd38598e61d4145a6cd1a941279ebf1,

title = "Expected Net Present Value of Sample Information: from burden to investment",

abstract = "The Expected Value of Information Framework has been proposed as a method for identifying when health care technologies should be immediately reimbursed and when any reimbursement should be withheld while awaiting more evidence. This framework assesses the value of obtaining additional evidence to inform a current reimbursement decision. This represents the burden of not having the additional evidence at the time of the decision. However, when deciding whether to reimburse now or await more evidence, decision makers need to know the value of investing in more research to inform a future decision. Assessing this value requires consideration of research costs, research time, and what happens to patients while the research is undertaken and after completion. The investigators describe a development of the calculation of the expected value of sample information that assesses the value of investing in further research, including an only-in-research strategy and an only-with-research strategy.",

keywords = "Statistics",

author = "Hall, {Peter S} and Richard Edlin and Kharroubi, {Samer A.} and Walter Gregory and Christopher McCabe",

year = "2012",

month = may,

doi = "10.1177/0272989X12443010",

language = "English",

volume = "32",

pages = "E11--E21",

journal = "Medical Decision Making",

issn = "0272-989X",

publisher = "SAGE",

number = "3",

}

TY - JOUR

T1 - Expected Net Present Value of Sample Information

T2 - from burden to investment

AU - Hall, Peter S

AU - Edlin, Richard

AU - Kharroubi, Samer A.

AU - Gregory, Walter

AU - McCabe, Christopher

PY - 2012/5

Y1 - 2012/5

N2 - The Expected Value of Information Framework has been proposed as a method for identifying when health care technologies should be immediately reimbursed and when any reimbursement should be withheld while awaiting more evidence. This framework assesses the value of obtaining additional evidence to inform a current reimbursement decision. This represents the burden of not having the additional evidence at the time of the decision. However, when deciding whether to reimburse now or await more evidence, decision makers need to know the value of investing in more research to inform a future decision. Assessing this value requires consideration of research costs, research time, and what happens to patients while the research is undertaken and after completion. The investigators describe a development of the calculation of the expected value of sample information that assesses the value of investing in further research, including an only-in-research strategy and an only-with-research strategy.

AB - The Expected Value of Information Framework has been proposed as a method for identifying when health care technologies should be immediately reimbursed and when any reimbursement should be withheld while awaiting more evidence. This framework assesses the value of obtaining additional evidence to inform a current reimbursement decision. This represents the burden of not having the additional evidence at the time of the decision. However, when deciding whether to reimburse now or await more evidence, decision makers need to know the value of investing in more research to inform a future decision. Assessing this value requires consideration of research costs, research time, and what happens to patients while the research is undertaken and after completion. The investigators describe a development of the calculation of the expected value of sample information that assesses the value of investing in further research, including an only-in-research strategy and an only-with-research strategy.

KW - Statistics

UR - http://www.scopus.com/inward/record.url?scp=84861829485&partnerID=8YFLogxK

U2 - 10.1177/0272989X12443010

DO - 10.1177/0272989X12443010

M3 - Article

VL - 32

SP - E11-E21

JO - Medical Decision Making

JF - Medical Decision Making

SN - 0272-989X

IS - 3

ER -

Expected Net Present Value of Sample Information: from burden to investment

Abstract

Keywords

Access to Document

Other files and links

Cite this